Curis Inc. (CRIS)
NASDAQ: CRISHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
CRIS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.72M
- P/E (TTM)
- 0.54
- EPS (TTM)
- $1.32
- Dividend yield
- None
- 52-week range
- 0.61 – 33.60
- Day range
- 0.613 – 0.8199
- Volume / Avg
- 426.38K / 199.15K
- Beta
- —
- Shares outstanding
- 2.43M
- Next earnings
- Nov 5, 2026
52-week range
CRIS stock today
On Oct 8, CRIS ended the session at $0.7094, shedding $0.0272 (3.69%), versus the S&P 500's 0.47% decline. Volume was 2.1x the average at 426.38K shares, a sign of unusually heavy trading. Shares are 97.9% below their 52-week high of $33.60 and 16.3% above the 52-week low of $0.61, near the bottom of the past year's range.
Curis trades at 0.5x its trailing twelve-month earnings per share of $1.32. Curis's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Curis
Company profileCuris, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. James E. Dentzer
- Headquarters
- Lexington, MA
- Employees
- 20
- Website
- curis.com
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$42.67+5914.94%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-2.29
Curis peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EDVAEndovia Health Sciences Inc. | 0.1599 | -3.09% | $1.77M | vs CRIS |
| SCNIScinai Immunotherapeutics Ltd. ADR | 1.21 | +7.08% | $1.64M | vs CRIS |
| ARTLArtelo Biosciences Inc. | 3.37 | -1.17% | $1.85M | vs CRIS |
| LABTLakewood-Amedex Biotherapeutics Inc. | 0.792 | -6.80% | $1.88M | vs CRIS |
| VBIOValion Bio Inc. | 2.21 | +0.91% | $1.96M | vs CRIS |
| OGENOragenics Inc. | 0.463 | -7.38% | $2.09M | vs CRIS |
| BBLGBone Biologics Corp | 0.4691 | -3.77% | $1.29M | vs CRIS |
| GNPXGenprex Inc. | 2.75 | +4.96% | $2.25M | vs CRIS |
Indexes, lists and sector
Appears in lists
Curis stock FAQ
What is Curis's stock price today?
CRIS last traded at $0.7094 as of Oct 8, 4:00 PM EDT, down 3.69% on the day. Prices are delayed at least 15 minutes.
When is Curis's next earnings date?
Curis is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-2.29.
What is CRIS's P/E ratio?
CRIS trades at a trailing P/E ratio of 0.54.
Who is Curis's CEO?
Mr. James E. Dentzer is the chief executive officer of Curis Inc., which has about 20 employees.
What is the CRIS 52-week high?
The 52-week high for CRIS is $33.60 and the 52-week low is $0.61. The stock is currently 97.9% below its high.